Canada warns on illegal retatrutide sales as US seizures of illicit GLP-1s climb
Retatrutide is not approved anywhere and is still in Phase 3 trials, so any product sold under that name is unregulated, while US seizures of illicit GLP-1 shipments have risen sharply.
A warning about unapproved and illegal sales of retatrutide was issued in Canada on August 18, extending the gray market for Eli Lilly's experimental weight-loss drug beyond the United States [1]. An Axios report on August 24 said US Customs and Border Protection intercepted more than 690 shipments of illicit GLP-1 drugs in all of fiscal 2025 — and more than 1,400 in July 2026 alone [1].
Retatrutide is not approved for sale in any country, and no application for approval has been submitted anywhere [1]. It is a triple agonist that acts on the GLP-1, GIP and glucagon receptors and is being developed by Eli Lilly; it remains in Phase 3 testing [1]. In the TRIUMPH-1 trial, the drug produced average weight loss of 28.3 percent at 80 weeks [1]. Two further Phase 3 trials, TRIUMPH-2 and TRIUMPH-3, read out on July 23, 2026, and Lilly has guided to a BLA filing in the first quarter of 2027 [1].
That timeline leaves the drug well short of a US approval decision, and further still from a pharmacy. Any retatrutide sold today is an unapproved product, whatever a seller says about what is in it.
The enforcement figures point to scale rather than a handful of listings. More than 1,400 illicit GLP-1 shipments were intercepted in the single month of July 2026, against more than 690 in the whole of fiscal 2025 [1]. What the seized shipments contained and what happened to them after seizure has not been reported. Which Canadian body issued the August 18 warning, and whether any sellers were named, has not been disclosed either.
The market that retatrutide would enter already has approved products. The FDA-approved GLP-1 options include semaglutide, sold as Ozempic, Wegovy and Rybelsus; tirzepatide, sold as Mounjaro and Zepbound; and orforglipron, sold as Foundayo, which was approved in April 2026 [1]. Retatrutide is not among them, and no date has been announced for a regulatory decision on it.
Why it matters for patients
Retatrutide has not been reviewed or approved by any regulator [1]. That means there is no approved version of the drug, no standard dose, and no label information for it. A buyer has no way to confirm from the outside what a vial contains, how much active ingredient it holds, or how it was made.
The numbers reported this month show the supply is moving in volume, not trickling. A single month in 2026 produced more than twice the intercepted shipments of the entire prior fiscal year [1], and the market has now drawn a warning in Canada as well [1]. Shipments that are intercepted are stopped; the ones that are not are the ones that reach buyers.
The trial figures attached to retatrutide, including the 28.3 percent average weight loss in TRIUMPH-1 [1], come from a controlled research setting. They describe an investigational drug given under study conditions, not a product sold online. Results from the remaining Phase 3 trials have not yet been reported [1].
What happens next
The remaining retatrutide Phase 3 readouts are expected in the second half of 2026, with Lilly guiding to a BLA filing in the first quarter of 2027 [1]. A filing is a submission, not an approval, and no decision date has been announced.
Separately, Novo Nordisk's CagriSema faces an FDA decision in the second half of 2026 as the first once-weekly GLP-1 plus amylin combination for weight management, with roughly 23 percent weight loss reported [1]. Retatrutide would reach the market, if it is approved, after that.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.